Max Lataillade - Concepedia

Author

Max Lataillade

Bristol-Myers Squibb (United States)ORCID

Also Known As

Berenguer, J., George J Hanna, M Lataillade, M. Lataillade, Madruga, Jose V., Max Lataillade, Max Lataillade (183356)

Publications

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)GlaxoSmithKline (United States)Yale University Hospital Nacional Cayetano Heredia Triangle

About

Max Lataillade is an author at Bristol-Myers Squibb (United States) specializing in medicine, hiv, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	620
2	Health Sciences	1	1	28
3	Natural Sciences	1	1	20
4	Biomolecular Engineering	1	1	20
5	Epidemiology	1	1	169

Max Lataillade

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría, JAIDS Journal of Acquired Immune Deficiency Syndromes	2010	253
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection Judith A. Aberg, Gilles Pialoux, Pedro Cahn, New England Journal of Medicine Multidrug-resistant Hiv-1 InfectionAntiretroviral DrugsHuman RetrovirusImmunologyAntiviral Response	2020	169
Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor Resistance Max Lataillade, Jennifer Chiarella, Michael J. Kozal Antiviral Therapy	2007	146
<i>In Vitro</i>Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068 Beata Nowicka-Sans, Yi-Fei Gong, Brian McAuliffe, Antimicrobial Agents and Chemotherapy Prodrug Bms-663068Hiv-1 Gp120MedicineImmunologyAntiviral Response	2012	137
Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study Max Lataillade, Jennifer Chiarella, Rong Yang, PLoS ONE	2010	130
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study Max Lataillade, Jacob Lalezari, Judith A. Aberg, The Lancet HIV Week 96Treatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyBrighte Study	2020	87
A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results Michael J. Kozal, Sergio Lupo, Edwin DeJesus, HIV Clinical Trials	2012	85
Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors Zhufang Li, Nannan Zhou, Yongnian Sun, Antimicrobial Agents and Chemotherapy	2013	76
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068 Nannan Zhou, Beata Nowicka-Sans, Brian McAuliffe, Journal of Antimicrobial Chemotherapy	2013	75
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial Jacob Lalezari, Gulam Latiff, Cynthia Brinson, The Lancet HIV Treatment And PreventionPhase 2BPharmacologyClinical TrialsAntiviral Therapy	2015	67

Page 1